Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G.
Chien KS, et al. Among authors: dong xq.
Br J Haematol. 2021 Nov;195(3):378-387. doi: 10.1111/bjh.17689. Epub 2021 Aug 2.
Br J Haematol. 2021.
PMID: 34340254
Clinical Trial.